The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis in Adults.

Inclusion Criteria:

• Signed Consent of the patient;
• Clinical diagnosis of moderate - severe persistent allergic rhinitis according to ARIA classification(Allergic Rhinitis and Its Impact on Asthma);
• Adults aged ≥ 18 years old;
• Evidence of sensitization to aeroallergens in examination (immediate skin tests or serum specific IgE) in the 12 months prior to inclusion.

Exclusion Criteria:

• Decongestants dependent patients or patients receiving allergen specific immunotherapy;
• Patients who were in use of oral antihistamines or decongestants in the past 15 days;
• Patients who were treated with systemic corticosteroids in the last month;
• Patients on treatment with monoamine oxidase inhibitors (MAOIs);
• Patients with history of hypersensitivity to any of the formula compounds;
• Patients with any clinically significant disease that in the investigator opinion can not participate in the study
• Patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and nasal anatomic abnormalities.
• Participation in clinical trial in 30 days prior to study entry;